Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating

Pfizer Inc. (NYSE:PFE) is one of the 10 Best Affordable Stocks Under $50 to Buy. On August 5, Morgan Stanley increased its price target for Pfizer Inc. (NYSE:PFE) from $32 to $33 while keeping an Equalweight rating.

This decision came after Pfizer Inc. (NYSE:PFE) released its Q2 2025 earnings report. The company continues to navigate policy changes in the pharmaceutical sector.

Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating

The firm highlighted that Pfizer Inc.’s (NYSE:PFE) guidance accounts for the impact of tariffs from China, Canada, and Mexico. It also reflects potential price changes based on a recent letter received from President Trump.

In its outlook, Pfizer Inc. (NYSE:PFE) reaffirmed its full-year 2025 revenue guidance. The company increased its adjusted diluted EPS forecast by $0.10 at the midpoint to a range of $2.90 to $3.10.

This higher adjusted diluted EPS guidance is supported by Pfizer Inc.’s (NYSE:PFE) strong performance, continued confidence in the company’s business, a favorable impact from foreign exchange, cost improvement initiatives, and an improved effective tax rate.

Pfizer Inc. (NYSE:PFE) is a leading pharmaceutical company that focuses on the discovery, development, and manufacture of healthcare products, medicines, and vaccines.

While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.